← Back to Search

Other

CBL-514 Injection for Subcutaneous Fat

Phase 2
Waitlist Available
Research Sponsored by Caliway Biopharmaceuticals Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from visit 2 (baseline) up to 8 weeks after last treatment
Awards & highlights

Study Summary

This trialwill test a new drug to see if it's safe, effective, and if patients like it.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from visit 2 (baseline) up to 8 weeks after last treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and from visit 2 (baseline) up to 8 weeks after last treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of subjects who lose at least 150 mL of subcutaneous fat compared with placebo
Secondary outcome measures
Change of subcutaneous fat volume over the treated area compared with placebo
Change of subcutaneous fat volume over the treated area of the CBL-514 group compared with individual baseline
Evaluation of safety following up to 4 courses of CBL-514 compared with placebo
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: CBL-514 InjectionExperimental Treatment1 Intervention
Participant will receive CBL-514 administered in 2.4 mL injections, up to 120 mL per treatment session at intervals of approximately 4 weeks for up to a maximum of 4 treatments.
Group II: Placebo: 0.9% Sodium ChloridePlacebo Group1 Intervention
Participant will receive 0.9% Sodium Chloride administered in 2.4 mL injections, up to 120 mL per treatment session at intervals of approximately 4 weeks for up to a maximum of 4 treatments.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CBL-514 Injection
2022
Completed Phase 2
~80

Find a Location

Who is running the clinical trial?

Caliway Biopharmaceuticals Co., Ltd.Lead Sponsor
10 Previous Clinical Trials
462 Total Patients Enrolled
6 Trials studying Subcutaneous Fat
385 Patients Enrolled for Subcutaneous Fat
Anne SheuStudy DirectorCaliway Biopharmaceuticals Co., Ltd.
6 Previous Clinical Trials
324 Total Patients Enrolled
3 Trials studying Subcutaneous Fat
277 Patients Enrolled for Subcutaneous Fat

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Massachusetts
New York
South Carolina
Other
How old are they?
18 - 65
What site did they apply to?
Investigational site 3
Investigational site 2
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
1

Why did patients apply to this trial?

I have been struggling with losing fat and maintaining muscle. I like that this doesn’t damage tissue!
PatientReceived 1 prior treatment
Recent research and studies
clinicaltrials.govStudy
A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)
2022. "A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04897412.
~24 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top